Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART.

Prostratin is a unique phorbol ester that stimulates protein kinase C activity but is nontumor promoting. Remarkably, prostratin is also able to inhibit de novo human immunodeficiency virus type 1 (HIV-1) infection yet up-regulate viral expression from latent proviruses. Prostratin's lack of tumor promotion, coupled with its ability to block viral spread yet induce latent proviral expression, prompted studies to determine whether this compound could serve as an inductive adjuvant therapy for patients treated with highly active antiretroviral therapy (HAART). The current experiments indicate that prostratin is a potent mitogen for mononuclear phagocytes possessing many of the activities of phorbol myristate acetate (PMA) with notable functional differences. Prostratin, like PMA, accelerates differentiation of the myeloid cell-lines, HL-60 and THP-1, as well as mononuclear phagocytes from bone marrow and peripheral blood. Enzyme-linked immunosorbent assay and gene array analyses indicate significant changes in the expression of proteins and messenger RNA after treatment of cells with prostratin, consistent with phagocyte activation and differentiation. Prostratin blocks HIV-1 infection relating to down-regulation of CD4 receptor expression. The array analysis indicates a similar down-regulation of the HIV-1 coreceptors, CXCR4 and CCR5, and this may also reduce viral infectivity of treated host cells. Finally, prostratin is capable of up-regulating HIV-1 expression from CD8+ T lymphocyte-depleted peripheral blood mononuclear cells of patients undergoing HAART. This novel observation suggests the agent may be an excellent candidate to augment HAART by inducing expression of latent HIV-1 with the ultimate goal of eliminating persistent viral reservoirs in certain individuals infected with HIV-1.

[1]  Hui Zhang,et al.  Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups. , 2001, The Journal of infectious diseases.

[2]  D. Purcell,et al.  Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy , 2001, AIDS.

[3]  I. Fidler,et al.  Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells. , 2000, Cancer research.

[4]  Yong Woo Lee,et al.  Dexamethasone inhibits IL-1β gene expression in LPS-stimulated RAW 264.7 cells by blocking NF-κB/Rel and AP-1 activation , 2000 .

[5]  E. Clark,et al.  Osteoprotegerin Is an αvβ3-induced, NF-κB-dependent Survival Factor for Endothelial Cells* , 2000, The Journal of Biological Chemistry.

[6]  P. Cox Will Tribal Knowledge Survive the Millennium? , 2000, Science.

[7]  E. Clark,et al.  Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. , 2000, The Journal of biological chemistry.

[8]  Y. W. Lee,et al.  Dexamethasone inhibits IL-1 beta gene expression in LPS-stimulated RAW 264.7 cells by blocking NF-kappa B/Rel and AP-1 activation. , 2000, Immunopharmacology.

[9]  C H Fox,et al.  Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. , 1999, AIDS.

[10]  J Witek,et al.  Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. , 1999, JAMA.

[11]  M. Dybul,et al.  Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy , 1999, Nature Medicine.

[12]  A. Perelson,et al.  Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. , 1999, The New England journal of medicine.

[13]  C. A. Macken,et al.  Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. , 1999, The New England journal of medicine.

[14]  D. Prockop,et al.  Human immunodeficiency virus type 1 Vpr alters bone marrow cell function. , 1999, Blood.

[15]  Hui Zhang,et al.  Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. , 1998, The New England journal of medicine.

[16]  T. Chun,et al.  Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[17]  A. Aranda,et al.  Insulin-like growth factor-1 stimulates rat prolactin gene expression by a Ras, ETS and phosphatidylinositol 3- kinase dependent mechanism , 1998, Oncogene.

[18]  M A Nowak,et al.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[20]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[21]  H. Handa,et al.  Characterization of the Human Thrombopoietin Gene Promoter , 1997, The Journal of Biological Chemistry.

[22]  K. Gustafson,et al.  Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV). , 1997, Antiviral research.

[23]  P. Kiener,et al.  Activation of human monocytes through CD40 induces matrix metalloproteinases. , 1996, Journal of immunology.

[24]  C. Janeway Immunobiology: The Immune System in Health and Disease , 1996 .

[25]  G. Bren,et al.  Protein kinase C-zeta mediates NF-kappa B activation in human immunodeficiency virus-infected monocytes , 1996, Journal of virology.

[26]  M. Kitamura,et al.  Dual regulation of IL-1 beta-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-kappa B and AP-1. , 1996, The American journal of physiology.

[27]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[28]  S. Arya,et al.  Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. , 1995, Science.

[29]  A. Bergamini,et al.  Macrophage colony-stimulating factor enhances the susceptibility of macrophages to infection by human immunodeficiency virus and reduces the activity of compounds that inhibit virus binding. , 1994, Blood.

[30]  D. Klatzmann,et al.  Characterization of the human CD4 gene promoter: transcription from the CD4 gene core promoter is tissue-specific and is activated by Ets proteins. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Z. Szallasi,et al.  Nonpromoting 12-deoxyphorbol 13-esters inhibit phorbol 12-myristate 13-acetate induced tumor promotion in CD-1 mouse skin. , 1993, Cancer research.

[32]  Z. Szallasi,et al.  Non-promoting 12-deoxyphorbol 13-esters as potent inhibitors of phorbol 12-myristate 13-acetate-induced acute and chronic biological responses in CD-1 mouse skin. , 1992, Carcinogenesis.

[33]  Z. Szallasi,et al.  A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. , 1992, Journal of medicinal chemistry.

[34]  Z. Szallasi,et al.  Prostratin, a nonpromoting phorbol ester, inhibits induction by phorbol 12-myristate 13-acetate of ornithine decarboxylase, edema, and hyperplasia in CD-1 mouse skin. , 1991, Cancer research.

[35]  S. Collins,et al.  The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. , 1987, Blood.

[36]  F. Marks,et al.  Skin tumor promotion by phorbol esters is a two-stage process. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Shigeru Tsuchiya,et al.  Establishment and characterization of a human acute monocytic leukemia cell line (THP‐1) , 1980, International journal of cancer.

[38]  S. Collins,et al.  Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. , 1979, Blood.